pcDNA3.1-mNRDc-V5
(Plasmid
#51297)
-
Purposeexpression of mouse NRDc in mammalian cells
-
Depositing Lab
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 51297 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3.1
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 5500
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameNRDc
-
Alt nameNrd1
-
Alt namenardilysin
-
Alt nameN-arginine dibasic convertase
-
SpeciesM. musculus (mouse)
-
GenBank ID230598
-
Entrez GeneNrd1 (a.k.a. RP23-188A12.1, 2600011I06Rik, AI875733, NRD-C)
- Promoter CMV
-
Tags
/ Fusion Proteins
- V5 (C terminal on backbone)
- HIS (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site XhoI (not destroyed)
- 3′ cloning site XbaI (not destroyed)
- 5′ sequencing primer CMV-F
- 3′ sequencing primer BGHrev (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pcDNA3.1-mNRDc-V5 was a gift from Eiichiro Nishi (Addgene plasmid # 51297 ; http://n2t.net/addgene:51297 ; RRID:Addgene_51297) -
For your References section:
Critical roles of nardilysin in the maintenance of body temperature homoeostasis. Hiraoka Y, Matsuoka T, Ohno M, Nakamura K, Saijo S, Matsumura S, Nishi K, Sakamoto J, Chen PM, Inoue K, Fushiki T, Kita T, Kimura T, Nishi E. Nat Commun. 2014;5:3224. doi: 10.1038/ncomms4224. 10.1038/ncomms4224 PubMed 24492630